Display Settings:

Format

Send to:

Choose Destination
Antimicrob Agents Chemother. 2004 Dec;48(12):4864-8.

Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance.

Author information

  • 1Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California 94305, USA.

Abstract

We observed a previously uncharacterized mutation in the protease substrate cleft, L23I, in 31 of 4,303 persons undergoing human immunodeficiency virus type 1 genotypic resistance testing. In combination with V82I, L23I was associated with a sevenfold reduction in nelfinavir susceptibility and a decrease in replication capacity. In combination with other drug resistance mutations, L23I was associated with multidrug resistance and a compensatory increase in replication capacity.

PMID:
15561868
[PubMed - indexed for MEDLINE]
PMCID:
PMC529213
Free PMC Article

Images from this publication.See all images (1)Free text

FIG. 1.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk